Sanofi (SNY): Today's Featured Drugs Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Sanofi ( SNY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.2%. By the end of trading, Sanofi fell $1.19 (-2.3%) to $50.16 on average volume. Throughout the day, 1,695,655 shares of Sanofi exchanged hands as compared to its average daily volume of 2,109,500 shares. The stock ranged in price between $49.75-$50.49 after having opened the day at $49.82 as compared to the previous trading day's close of $51.35. Other companies within the Drugs industry that declined today were: Biostar Pharmaceuticals ( BSPM), down 12.2%, Allergan ( AGN), down 11.6%, Cell Therapeutics ( CTIC), down 10.7% and Senesco Technologies ( SNTI), down 10.3%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Sanofi researches, develops, manufactures, and markets healthcare products worldwide. The company operates through Pharmaceuticals, Human Vaccines, and Animal Health segments. Sanofi has a market cap of $136.5 billion and is part of the health care sector. The company has a P/E ratio of 27.4, above the S&P 500 P/E ratio of 17.7. Shares are up 8.4% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Sanofi a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance and expanding profit margins. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, Isis Pharmaceuticals ( ISIS), down 29.2%, Hyperion Therapeutics ( HPTX), down 8.9%, Halozyme Therapeutics ( HALO), down 8.7% and Synthetic Biologics ( SYN), down 8.5% , were all gainers within the drugs industry with Illumina ( ILMN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Boeing Slides as China Premier Li Says Willing to Continue Talks With Airbus

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Trump, Trade Wars, General Electric, 'Jurassic World' - 5 Things You Must Know

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Stocks Weaken Around The World as Trump Opens New Fronts in Global Trade War

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Trump Puts Tech in Trade War Crosshairs With Planned Curb on China Investment

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come